Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.
Atanasova E., Milosevic D., Bornschlegl S., Krucker KP., Jacob EK., Carmona Porquera EM.
Prospective Study on Scar, published in Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Stem Cell Res Ther (2022)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 35101101
- DOI
- 10.1186/s13287-021-02692-0
Abstract (original English)
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive pulmonary disease characterized by aberrant tissue remodeling, formation of scar tissue within the lungs and continuous loss of lung function. The areas of fibrosis seen in lungs of IPF patients share many features with normal aging lung including cellular senescence. The contribution of the immune system to the etiology of IPF remains poorly understood. Evidence obtained from animal models and human studies suggests that innate and adaptive immune processes can orchestrate existing fibrotic responses. Currently, there is only modest effective pharmacotherapy for IPF. Mesenchymal stem cells (MSCs)-based therapies have emerged as a potential option treatment of IPF. This study characterizes the functionality of autologous MSCs for use as an IPF therapy and presents an attempt to determine whether the disease occurring in the lungs is associated with an alterated immune system. Comprehensive characterization of autologous adipose-derived MSCs (aMSCs) from 5 IPF patient and 5 age- and gender-matched healthy controls (HC) was done using flow cytometry, PCR (ddPCR), multiplex Luminex xMAP technology, confocal microscopy self-renewal capacity and osteogenic differentiation. Additionally, multi-parameter quantitative flow cytometry of unmanipulated whole blood of 15 IPF patients and 87 (30 age- and gender-matched) HC was us
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Clinical Applications of Autologous Fat Grafting in Pathological Hand Conditions.
Systematic Review with a reported sample of 7 on Osteoarthritis, Scar, published in J Hand Surg Asian Pac Vol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 7
J Hand Surg Asian Pac Vol - Level AMeta-analysisPubMed
Stem cell therapy in thin endometrium and Asherman's syndrome: a systematic review and meta-analysis.
Meta-analysis with a reported sample of 323 on Scar, published in Eur J Obstet Gynecol Reprod Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 323
Eur J Obstet Gynecol Reprod Biol - Level AMeta-analysisEurope PMC
Therapeutic value of mesenchymal stem cell-derived extracellular vesicles in hypertrophic and keloid scars: a systematic review and meta-analysis
Meta-analysis on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
Front Cell Dev Biol - Level AMeta-analysisPubMed
Efficacy and safety of autologous cell-based therapies for atrophic acne scar treatment: an updated systematic review and meta-analysis with in-depth methodological and clinical insights.
Meta-analysis with a reported sample of 500 on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 500
Front Cell Dev Biol - Level ASystematic ReviewEurope PMC
Comparative Efficacy and Safety of Fractional CO<sub>2</sub> Laser and Gold Microneedling Radiofrequency for Atrophic Acne Scars: A Systematic Review
Systematic Review on Chronic Wound, Scar, published in Skin Res Technol (2026) — summary generated from the PubMed abstract.
- 2026
Skin Res Technol - Level AMeta-analysisPubMed
Role of exosome therapy in reconstructive surgery: a review.
Meta-analysis on Chronic Wound, Scar, Immune Modulation, published in Front Med (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
Front Med (Lausanne)1 citations